Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Currently available complement inhibitors indiscriminately block both the alternative and the classical complement pathways, where in the latter is required for clearing infectious microorganisms.